34 patents
Utility
Humanized ANTI-CD45 Antibodies
11 Jan 24
Provided are humanized anti-human CD45 antibodies and pharmaceutical compositions including the antibodies.
Lequn ZHAO, Helen KOTANIDES
Filed: 11 Sep 23
Utility
Calreticulin Nanobodies
28 Dec 23
Provided are nanobodies that bind human calreticulin, fusion proteins including the nanobodies, pharmaceutical compositions including the nanobodies or fusion proteins, and radioconjugates of the nanobodies or fusion proteins.
GHOLAMREZA HASSANZADEH GHASSABEH, STEVE SCHOONOOGHE, HELEN KOTANIDES
Filed: 24 May 23
Utility
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
19 Dec 23
This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective.
Dragan Cicic
Filed: 16 May 22
Utility
Trophoblast Glycoprotein Radioimmunotherapy for the Treatment of Solid Cancers
7 Dec 23
Compositions and methods for treating a solid cancer in a subject by administering an effective amount of a radioisotope labeled trophoblast glycoprotein (5T4)-targeting agent are provided.
Dale L. LUDWIG, Eileen GEOGHEGAN
Filed: 13 Sep 21
Utility
Radioconjugates Targeting CD33 In the Treatment of Cancers
28 Sep 23
The invention provides compositions and methods for treating cancers and proliferative disorders, including solid tumor cancers and non-myeloid hematological malignancies, using radioconjugates targeting CD33, alone or in combination with one or more radioconjugates targeting other cancer-associated targets such as DR5, 5T4, HER2, HER3, and TROP2, antibody drug conjugates targeting these or other cancer-associated targets, therapeutic antibodies targeting these or other cancer-associated targets, chemotherapy agents and regimens, and immune checkpoint inhibitors.
Mary M. Chen, Avinash Desai, Dale L. Ludwig, Mark Berger, Sandesh Seth
Filed: 8 Aug 22
Utility
DR5 Radioimmunotherapy In the Treatment of Solid Cancers
28 Sep 23
Methods for treating a proliferative disease or disorder by administering an antibody radio-conjugate alone or in combination with an immune checkpoint therapy such as an antibody against an immune checkpoint inhibitor, and/or a DNA damage response inhibitor.
Dale LUDWIG, Eileen GEOGHEGAN
Filed: 23 Jun 21
Utility
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
10 Aug 23
Provided are compositions and methods for treating a solid cancer such as a HER3-positive tumor in a subject by administering an effective amount of a HER3-targeting agent labeled with a radionuclide such as 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, or 212Pb, alone or in combination with other therapeutic agents or modalities such as VEGF or VEGFR inhibitors.
DALE L LUDWIG, Eileen Geoghegan, Sandesh Seth, Paul Diamond
Filed: 23 Dec 22
Utility
CorrectedCombination Therapy for Treatment of a Hematological Disease
27 Apr 23
Methods for treating a hematological disease or disorder or a solid cancer by administering an effective amount of a combination immunotherapy including an antibody against an epitope of CD33 and an antibody against an epitope of CD38 are disclosed.
Sandesh SETH, Keisha THOMAS
Filed: 13 Nov 18
Utility
Radioconjugates Targeting CD33 In the Treatment of Cancers
23 Mar 23
The invention provides compositions and methods for treating cancers and proliferative disorders, including solid tumor cancers and non-myeloid hematological malignancies, using radioconjugates targeting CD33, alone or in combination with one or more radioconjugates targeting other cancer-associated targets such as DRS, 5T4, HER2, HER3, and TROP2, antibody drug conjugates targeting these or other cancer-associated targets, therapeutic antibodies targeting these or other cancer-associated targets, chemotherapy agents and regimens, and immune checkpoint inhibitors.
Mary M. Chen, Avinash Desai, Dale L. Ludwig, Mark Berger
Filed: 26 Aug 22
Utility
Radiolabeling of ANTI-CD45 Immunoglobulin and Methods of Use Thereof
1 Dec 22
Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein.
Dale LUDWIG, Sandesh SETH
Filed: 17 Sep 20
Utility
Combination Radioimmunotherapy and CD47 Blockade In the Treatment of Cancer
15 Sep 22
Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRPα-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRPα.
Dale L Ludwig, Sandesh Seth, Paul Diamond
Filed: 21 Apr 22
Utility
Method for Treating Cancer Using a BCL-2 Inhibitor In Conjunction with an Alpha-emitting Radioimmunotherapeutic
1 Sep 22
This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective.
Dragan Cicic
Filed: 16 May 22
Utility
Combination Radioimmunotherapy and CD47 Blockade In the Treatment of Cancer
11 Aug 22
Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRPα-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRPα.
Dale L Ludwig, Sandesh Seth, Paul Diamond
Filed: 20 Apr 22
Utility
Stabilized radiolabeled anti-CD45 immunoglobulin compositions
9 Aug 22
Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition.
Kaushik J. Dave, Shubh D. Sharma
Filed: 11 Mar 19
Utility
Compositions and Methods of Immunodepletion for the Treatment of Malignant and Non-malignant Hematological Diseases
30 Jun 22
Compositions and methods for transient immunodepletion of specific subsets of a subject's immune cells are disclosed.
Dale Ludwig, Eileen Geoghegan
Filed: 24 Apr 20
Utility
Method for treating cancer using a BCL-2 inhibitor in conjunction with an alpha-emitting radioimmunotherapeutic
21 Jun 22
This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a BCL-2 inhibitor in conjunction with (ii) an alpha-emitting isotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the BCL-2 inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective.
Dragan Cicic
Filed: 26 Apr 18
Utility
HER3 Radioimmunotherapy for the Treatment of Solid Cancers
12 May 22
Provided are compositions and methods for treating a solid cancer such as a HER3-positive tumor in a subject by administering an effective amount of a HER3-targeting agent labeled with a radionuclide such as 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, or 212Pb, alone or in combination with other therapeutic agents or modalities.
Dale L Ludwig, Eileen Geoghegan, Sandesh Seth, Paul Diamond
Filed: 22 Nov 21
Utility
Antibodies Conjugated With Actinium-225 and Actinium-227, and Related Compositions and Methods
28 Apr 22
This invention provides a compositions of matter comprising a therapeutic protein population (such as a HuM195 antibody population) wherein (a) each therapeutic protein in the population is conjugated to one or more actinium atoms, (b) each actinium atom is either 227Ac or 225Ac, and (c) the molar ratio of 227Ac to 225Ac in the composition is at least 1:1, This invention also provides related synthetic compositions and methods, as well as methods for treating hematologic malignancies.
Dale Ludwig, Steve O'Loughlin, Vimal Patel, Nitya Ray, Sandesh Seth
Filed: 27 Nov 19
Utility
Stabilized Radiolabeled ANTI-CD45 Immunoglobulin Compositions
21 Apr 22
Compositions and methods are described for stabilizing a radio-iodinated monoclonal IgG antibody for up to 17 days against radiolytic decomposition.
Kaushik DAVE, Shubh SHARMA
Filed: 28 Dec 21
Utility
Low dose antibody-based methods for treating hematologic malignancies
5 Apr 22
This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low peripheral cancerous cell burden.
Dragan Cicic
Filed: 25 May 17